KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) FCF Margin (2016 - 2025)

Historic FCF Margin for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to 0.3%.

  • Neogenomics' FCF Margin rose 12300.0% to 0.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.4%, marking a year-over-year increase of 9400.0%. This contributed to the annual value of 5.15% for FY2024, which is 400.0% up from last year.
  • Latest data reveals that Neogenomics reported FCF Margin of 0.3% as of Q3 2025, which was up 12300.0% from 7.72% recorded in Q2 2025.
  • In the past 5 years, Neogenomics' FCF Margin ranged from a high of 7.72% in Q2 2025 and a low of 31.8% during Q1 2022
  • For the 5-year period, Neogenomics' FCF Margin averaged around 10.86%, with its median value being 11.79% (2021).
  • Per our database at Business Quant, Neogenomics' FCF Margin plummeted by -208800bps in 2021 and then soared by 193400bps in 2022.
  • Neogenomics' FCF Margin (Quarter) stood at 25.26% in 2021, then surged by 77bps to 5.93% in 2022, then soared by 216bps to 6.9% in 2023, then plummeted by -115bps to 1.05% in 2024, then skyrocketed by 129bps to 0.3% in 2025.
  • Its FCF Margin stands at 0.3% for Q3 2025, versus 7.72% for Q2 2025 and 17.75% for Q1 2025.